Introduction: Targeted therapies have dramatically changed the treatment landscape of chronic lymphocytic leukemia (CLL). Current paradigms include combinations with small molecules (Bruton tyrosine kinase and B-cell lymphoma 2 inhibitors), chemotherapy, anti-CD20 monoclonal antibodies. Although chemotherapy-free regimens, such as single-agent venetoclax + rituximab, shown efficacy in heavily p...

Two recently published articles from Siegers and colleagues detail both a novel human gamma delta T cell (GDTc) expansion protocol and a bioluminescent xenograft model of Ph(+) leukemia, in which GDTc adoptive therapy was tested. Additionally, B-cell chronic lymphocytic leukemia-derived cells were newly identified as targets of preferentially expanded Vdelta1 GDTc.

The rapid progress in next-generation sequencing technologies has significantly contributed to our knowledge of the genetic events associated with the development, progression and treatment resistance of chronic lymphocytic leukemia patients. Together with the discovery of new driver mutations, next-generation sequencing has revealed an immense degree of both intra- and inter-tumor heterogeneit...

BACKGROUND A subset of patients with fludarabine-resistant chronic lymphocytic leukemia has previously been shown to express elevated intracellular levels of the concentrative high-affinity fludarabine transporter hCNT3, without any detectable related activity. We have recently shown that all-trans-retinoic acid is capable of inducing hCNT3 trafficking to plasma membrane in the MEC1 cell line. ...

Systemic mastocytosis with associated clonal haematological non-mast cell lineage disease (SM-AHNMD) is a heterogeneous group of mast cell disorders with different clinical, pathologic and underlying molecular characteristics. While myelomonocytic/myeloid neoplasia overwhelmingly predominates the AHNMD component, lymphoproliferative disorders rarely occur as an AHNMD component of SM-AHNMD. Here...